Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Impact · against what's priced in

Lexeo Therapeutics provides critical clinical trial parameters for the BLA-supportive SUNRISE-FA 2 study, including a 6-month efficacy timeline and LVMI primary endpoint. This information, combined with an upcoming JPM Healthcare Conference presentation, increases visibility and provides a clearer roadmap for the company's regulatory path.

LXEO+0.30: No priced-in read yet

Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

What matters in this story

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

What matters in this story

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

How each ticker is affected

Track these names every morning.

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Biotech stocks are surging. How investors can play the new drug innovation boom

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

What matters in this story

Next reads from the same story arc

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

What matters in this story

Next reads from the same story arc

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

How each ticker is affected

Track these names every morning.

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Biotech stocks are surging. How investors can play the new drug innovation boom

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial